Inclusion Criteria:

-

1. Generally healthy adults aged 18 years or older at the time of enrollment and
with a body mass index (BMI) of ≤30 kg/m2

- Completion of a prior COVID-19 primary vaccination course or booster (any
commercially available within the study country) at least 3 months prior to
enrollment OR recent clinically documented SARS-CoV-2 infection (by polymerase chain
reaction [PCR] or antibody test) in the past three months but not within one month
from enrollment.

- Willing to refrain from receiving an authorized COVID-19 booster dose until at least
90 days post IP administration.

- Female participants of child-bearing potential must have practiced adequate
contraception for 30 days before IP injection, have a negative pregnancy test on the
day of IP injection, and agree to continue adequate contraception until 180 days
after IP injection. (Please refer to Section 10.44 for the definition of
childbearing potential and adequate contraception).

- Male participants must agree to continue adequate contraception until 180 days after
IP injection.

- Able to consent to participate in the study and signed an Informed Consent Form
(ICF).

- Able and willing to complete all the scheduled study procedures during the whole
study period (approximately 6.5 months).

- Generally, in good health, as determined by a review of medical history and a
physical examination within 14 days prior to IP injection.

Exclusion Criteria:

-

1. History of anaphylaxis to key ingredients within the vaccine. 2. History of
seizure disorder, encephalopathy, or psychosis. 3. Female participant is
pregnant (positive urine pregnancy test), lactating, or plans to become
pregnant during the 180 days of enrollment. 4. Positive test result for human
immunodeficiency virus (HIV) or hepatitis B and C at Screening (test to be
performed at the discretion of the investigator based on medical history or
physical examination). 5. Positive result of lateral flow test for SARS-COV-2
on Day 0. 6. Laboratory (hematological and biochemistry) examination that is
out of normal range or greater than a Grade 2 abnormality. Grade 1
abnormalities will not be exclusionary if considered not clinically significant
by the investigator. Laboratory tests include: complete blood count (CBC),
prothrombin time (PT), partial thromboplastin time (PTT), alanine
aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase
(ALP), total bilirubin (T Bil), creatinine (CR), lipase, and blood glucose at
screening. 7. Transient mild laboratory abnormalities may be rescreened once,
and the participant will be excluded if the laboratory repeat test is abnormal
as per local laboratory normal values and the investigator's assessment. 8.
Presents with any acute febrile disease (oral temperature ≥37.5°C [99.5oF]) or
active infectious disease within 48 hours prior to IP injection. 9. Unstable
concomitant underlying conditions. Note: Stable condition defined as: the
participant is appropriately managed on consistent disease management; for
example, participants with well-controlled hypertension, adult-onset diabetes,
benign prostate hypertrophy, or hypothyroid disease will be eligible for
enrollment. The treatment regimen should be stable for at least 3 months prior
to entering the study. Once IP treatment has started, the patient must be
willing to maintain all aspects of the treatment regimen and forgo any elective
changes in medication or management. Emergency changes in medication or
management would be captured as an AE. 10. History of Guillain-Barre Syndrome
or degenerative neurological disorders; a history of autoimmune, inflammatory
disease or potential immune-mediated diseases (pIMD), or any condition that may
put the participant at increased risk of safety events. 11. History of serious
cardiovascular diseases, such as arrhythmia, conduction block, history of
myocardial infarction, and severe hypertension not controlled with medication.
12. History of immunodeficiency, asplenia, or functional asplenia. 13. History
of platelet disorder or other bleeding disorder that may cause contraindication
for IM injection. 14. Heavy smoker (>10 cigarettes per day), vaper (>1 mL of
e-liquid per day), or cannabis user ([near] daily use). Smokers have to agree
to use the same cigarette brand throughout the study.

15. History or diagnosis of coagulopathies. 16. Prior receipt of immunosuppressive
medication, cytotoxic therapy, or systemic corticosteroids within 6 months
before Day 0. 17. Recent receipt of blood products within 4 months before Day
0. 18. Administration of other investigational drugs within 3 months before Day
0 or planned use during the study period. 19. Currently has or a history of any
condition that, in the opinion of the investigator, may interfere with the
participant's compliance, evaluation of study objectives, or informed consent
process (i.e., medical, psychological, social, or other conditions).